Follow us on X
Follow us on LinkedIn
Latest News

Mission

Right Drug. Right Patient. Right Time.

Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable.

Currently, still too little is known about the molecular basis underpinning these diseases. In order to be able to better predict treatment response and potentially identify novel biomarkers leading to improved patient management and personalised therapy, a deeper understanding of the cellular mechanisms driving disease development is urgently needed.

In a never-before-seen effort 3TR sets out to fundamentally increase our knowledge of the molecular pathways and mechanisms linked to response and non-response to therapy in seven different immune-mediated, allergic and inflammatory diseases. It’s the largest immunology project funded by the Innovative Medicine Initiative (IMI) to date.

80 Million
80 Million
84 Months
84 Months
69 Partners
69 Partners
15 Countries
15 Countries

Ambition

Accelerating Precision Medicine for Immune-Mediated Diseases

“For the first time, the 3TR team will align and integrate the analysis of autoimmune, allergic, and inflammatory conditions to identify the relationship between longitudinal molecular and microbiome profiles in blood cells and tissues, and disease paths. This high-resolution multi-omics profiling analysis of individualised response to treatment and disease progression will facilitate stratification and identification of molecular patterns, helping us to improve patient management within these diseases in the long run.”

Marta Alarcón-Riquelme
Scientific Director of the GENYO centre at the Fundación Pública Andaluza Progreso y Salud and Scientific Coordinator of 3TR

Approach

Integrated, Cross-Disease Analysis of Seven Diseases
image/svg+xml